Plant Name: Rheum coreanum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| CNR1; HCAR2; CNR2; | |
| ALPL; RECQL; TDP1; BLM; PKM; HKDC1; PIK3CA; PIK3CB; HPGD; HSD11B1; HSD11B2; AKR1B1; HSD17B10; ALOX15; PGD; NQO2; ALDH1A1; ALOX12; GFER; USP2; UBE2N; UGT1A1; APEX1; POLB; | |
| PTPN1; CDC25B; | |
| GAA; | |
| BCL2; | |
| MET; MAP2K1; CSNK2A1; SYK; GRK6; CDK1; MAPK1; MAPK14; PIM1; | |
| CA7; CA5A; CA3; CA14; CA5B; CA1; CA12; CA9; CA13; CA4; CA6; CA2; | |
| RXRA; | |
| ESR1; ESR2; | |
| KDM4E; | |
| MAOA; ALOX5; PTGS1; PTGS2; XDH; | |
| KDM4A; L3MBTL1; SMN1;SMN2; | |
| ELANE; | |
| MMP2; MMP9; MMP1; | |
| BACE1; | |
| HIF1A; NFKB1; TP53; | |
| FUT7; | |
| SLC6A2; SLCO1B3; SLCO1B1; | |
| LMNA; MCL1; MAPT; HTT; GMNN; NPC1; APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HKDC1 | Putative hexokinase HKDC1 | Q2TB90 | CHEMBL1741200 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | HSD11B2 | 11-beta-hydroxysteroid dehydrogenase 2 | P80365 | CHEMBL3746 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | UBE2N | Ubiquitin-conjugating enzyme E2 N | P61088 | CHEMBL6089 |
| Enzyme_unclassified | UGT1A1 | UDP-glucuronosyltransferase 1-1 | P22309 | CHEMBL1287617 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Methyl-lysine/arginine binding protein | KDM4A | Lysine-specific demethylase 4A | O75164 | CHEMBL5896 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Nuclear hormone receptor subfamily 2 group B | RXRA | Retinoid X receptor alpha | P19793 | CHEMBL2061 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | Q02750 | CHEMBL3587 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | GRK6 | G protein-coupled receptor kinase 6 | P43250 | CHEMBL6144 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Serine protease | ELANE | Leukocyte elastase | P08246 | CHEMBL248 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | CNR1 | Cannabinoid CB1 receptor | P21554 | CHEMBL218 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Small molecule receptor (family A GPCR) | CNR2 | Cannabinoid CB2 receptor | P34972 | CHEMBL253 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | GMNN | Geminin | O75496 | CHEMBL1293278 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.990E-12 | 2.831E-09 | BLM, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, KDM4A, L3MBTL1, MMP1, MMP2, MMP9, NQO2, PTPN1, RXRA, TP53 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.688E-10 | 1.626E-07 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, XDH |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.430E-10 | 2.956E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 7.822E-10 | 4.154E-07 | CA2, CA7, CNR1, HCAR2, HIF1A, HTT, MAPK1, MAPK14, NPC1, PIK3CB, PTGS2, SYK |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.727E-09 | 8.173E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.175E-09 | 2.561E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 9.202E-09 | 3.131E-06 | ALOX12, ALOX15, ALOX5, HPGD, PTGS2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.014E-08 | 3.345E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, PTGS1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.207E-08 | 1.053E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 6.905E-08 | 1.566E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 8.321E-08 | 1.830E-05 | ALPL, CNR1, CNR2, CYP1A1, CYP1A2, ELANE, HPGD, MAPK14, NFKB1, PTGS2, UGT1A1 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.059E-07 | 2.260E-05 | ALPL, APEX1, APP, BLM, CYP1A1, CYP1B1, ESR1, MAPK1, NFKB1, NPC1, PTGS2, UGT1A1 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.317E-07 | 4.504E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 3.890E-07 | 7.179E-05 | BCL2, CA2, CA7, CNR1, HCAR2, HIF1A, HTT, MAPK1, MAPK14, NPC1, PIK3CB, PTGS2, SYK |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 4.085E-07 | 7.385E-05 | CDK1, MAP2K1, MAPK1, MAPK14, PIK3CB, PTPN1, SYK, UBE2N |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.168E-07 | 7.385E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 4.171E-07 | 7.385E-05 | APP, BCL2, BLM, CSNK2A1, ESR1, ESR2, HPGD, HTT, L3MBTL1, MAPK1, MAPT, MCL1, MET, MMP9, NFKB1, NQO2, PKM, PTGS2, SMN1, SMN2, TP53, UGT1A1, USP2, XDH |
| BP | GO:0008152; metabolic process | GO:0019318; hexose metabolic process | 6.838E-07 | 1.154E-04 | AKR1B1, ALDH1A1, FUT7, GAA, HKDC1, MAPK14, PIK3CA, PKM |
| BP | GO:0008152; metabolic process | GO:0010507; negative regulation of autophagy | 1.105E-06 | 1.783E-04 | BCL2, KDM4A, MCL1, MET, NPC1, PIK3CA |
| BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 1.349E-06 | 2.099E-04 | CA3, CDK1, CNR1, HPGD, POLB, TP53, UGT1A1 |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 2.242E-06 | 3.211E-04 | APEX1, BCL2, CA5A, CA5B, CDK1, CYP1A1, CYP1B1, ESR2, GFER, HKDC1, HSD17B10, MAOA, MAP2K1, MAPK1, MAPK14, MCL1, MMP2, NFKB1, PKM, TP53 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 3.426E-06 | 4.663E-04 | CYP3A4, ESR1, ESR2, HSD11B2, NPC1, UGT1A1 |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 6.120E-06 | 7.404E-04 | BCL2, HIF1A, MCL1, MMP9, PTGS2, PTPN1 |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 8.603E-06 | 9.509E-04 | BLM, RECQL, TP53 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 8.775E-06 | 9.650E-04 | AKR1B1, ALDH1A1, ALOX12, ALOX15, ALOX5, APP, BCL2, BLM, CA1, CA13, CA2, CA3, CA7, CDC25B, CDK1, CSNK2A1, GFER, GMNN, HIF1A, HKDC1, HPGD, HTT, KDM4A, LMNA, MAP2K1, MAPK1, MAPK14, MAPT, MCL1, NFKB1, NQO2, PGD, PIK3CA, PIK3CB, PIM1, PKM, PTPN1, SMN1, SMN2, SYK, TP53, UBE2N, XDH |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 9.039E-06 | 9.793E-04 | BCL2, MAPT, PTPN1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.908E-26 | 6.331E-22 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.374E-05 | 1.372E-03 | ALOX12, ALOX15, ALOX5, SYK |
| BP | GO:0023052; signaling | GO:0032228; regulation of synaptic transmission, GABAergic | 1.565E-05 | 1.514E-03 | CA2, CA7, CNR1, CNR2 |
| BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 1.588E-05 | 1.530E-03 | APP, CYP1B1, ESR1, ESR2, MAPK1, MAPK14, NFKB1, PIM1, SYK, UBE2N |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.678E-05 | 1.596E-03 | AKR1B1, ALOX5, APEX1, BCL2, BLM, CDC25B, CDK1, CSNK2A1, ESR1, ESR2, GMNN, HIF1A, HPGD, HTT, KDM4A, L3MBTL1, LMNA, MAPK1, MAPK14, MCL1, NFKB1, NQO2, PIM1, POLB, RECQL, RXRA, SMN1, SMN2, TP53, UBE2N, USP2 |
| BP | GO:0050896; response to stimulus | GO:0048585; negative regulation of response to stimulus | 1.881E-05 | 1.759E-03 | ALOX12, ALOX15, BCL2, CNR1, CNR2, CYP19A1, ELANE, ESR1, ESR2, HIF1A, HTT, LMNA, MAPK14, MCL1, MET, MMP9, NFKB1, PTGS2, PTPN1, XDH |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.230E-05 | 1.970E-03 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.244E-05 | 1.970E-03 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.244E-05 | 1.970E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 2.244E-05 | 1.970E-03 | PTGS1, PTGS2 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.244E-05 | 1.970E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.244E-05 | 1.970E-03 | ALOX12, ALOX15 |
| MF | GO:0005488; binding | GO:0008134; transcription factor binding | 2.307E-05 | 2.010E-03 | APEX1, BCL2, ESR1, GMNN, HIF1A, HTT, MAPK1, MAPK14, NFKB1, PIM1, RXRA, TP53 |
| BP | GO:0022414; reproductive process | GO:0060135; maternal process involved in female pregnancy | 2.822E-05 | 2.427E-03 | AKR1B1, CNR1, ESR1, RXRA |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 3.013E-05 | 2.553E-03 | CA2, CA4, CA9, HPGD, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0032502; developmental process | GO:0001525; angiogenesis | 3.041E-05 | 2.567E-03 | CYP1B1, HIF1A, MAPK14, MMP2, PIK3CA, PIK3CB, PTGS2, SYK |
| BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 3.142E-05 | 2.642E-03 | MMP2, MMP9, PTGS2, RXRA |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 3.525E-05 | 2.853E-03 | BCL2, CDK1, CSNK2A1, MAP2K1, MAPK1 |
| MF | GO:0003824; catalytic activity | GO:0032451; demethylase activity | 3.489E-05 | 2.853E-03 | CYP1A1, CYP1A2, KDM4A, KDM4E |
| BP | GO:0050896; response to stimulus | GO:0035094; response to nicotine | 4.264E-05 | 3.377E-03 | BCL2, CNR1, MAPK1, NFKB1 |
| MF | Unclassified; | GO:0004708; MAP kinase kinase activity | 4.564E-05 | 3.571E-03 | MAP2K1, MAPK1, MAPK14 |
| BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 5.598E-05 | 4.247E-03 | BCL2, MCL1, PIK3CA |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 6.130E-05 | 4.635E-03 | AKR1B1, APEX1, APP, NFKB1, PKM, TP53, TSHR |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.711E-05 | 4.904E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 6.711E-05 | 4.904E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 6.711E-05 | 4.904E-03 | CYP1A1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004949; cannabinoid receptor activity | 6.711E-05 | 4.904E-03 | CNR1, CNR2 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 6.711E-05 | 4.904E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 6.711E-05 | 4.904E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 7.016E-05 | 5.074E-03 | MAPK14, MAPT, PTGS2, TP53, XDH |
| BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 1.052E-04 | 6.985E-03 | APP, CDK1, MAPK1, MAPK14, PTGS2 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.117E-04 | 7.393E-03 | BCL2, CDK1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, HSD11B1, HSD11B2, PTGS1, PTGS2, UGT1A1 |
| BP | GO:0032501; multicellular organismal process | GO:0019233; sensory perception of pain | 1.180E-04 | 7.650E-03 | CNR1, CNR2, MAPK1, PTGS2 |
| MF | GO:0005488; binding | GO:0000166; nucleotide binding | 1.251E-04 | 8.061E-03 | ALDH1A1, BLM, CDK1, CSNK2A1, GFER, GRK6, HKDC1, HPGD, HSD11B2, MAP2K1, MAPK1, MAPK14, MET, NQO2, PIK3CA, PIK3CB, PIM1, PKM, RECQL, SYK, TP53, UBE2N, XDH |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.307E-04 | 8.272E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0007610; behavior | GO:0007611; learning or memory | 1.314E-04 | 8.293E-03 | APP, CNR1, HIF1A, HTT, MAPK1, MAPT, PTGS2 |
| BP | GO:0009987; cellular process | GO:0090170; regulation of Golgi inheritance | 1.338E-04 | 8.324E-03 | MAP2K1, MAPK1 |
| BP | GO:0009987; cellular process | GO:0038171; cannabinoid signaling pathway | 1.338E-04 | 8.324E-03 | CNR1, CNR2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.338E-04 | 8.324E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.338E-04 | 8.324E-03 | ESR1, ESR2 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.393E-04 | 8.594E-03 | BCL2, HIF1A, LMNA, PTGS2, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0001889; liver development | 1.457E-04 | 8.864E-03 | CSNK2A1, GFER, PIK3CA, PKM, UGT1A1 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.508E-04 | 9.065E-03 | HPGD, MMP2, MMP9 |
| BP | GO:0032502; developmental process | GO:0009653; anatomical structure morphogenesis | 1.523E-04 | 9.109E-03 | APP, BCL2, CA2, CA9, CYP1B1, ESR1, GAA, GMNN, HIF1A, HPGD, MAPK1, MAPK14, MET, MMP2, POLB, RXRA, SYK |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.664E-04 | 9.791E-03 | AKR1B1, CYP19A1, CYP1A2, NQO2, XDH |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.206E-18 | 5.252E-15 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 8.406E-18 | 3.051E-14 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.586E-25 | 4.913E-23 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.784E-12 | 3.595E-10 | CYP2C9; APP; MAP2K1; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.123E-11 | 1.344E-09 | MAP2K1; PKM; PIK3CA; HKDC1; MAPK1; PIK3CB; TP53; MET; HIF1A |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.128E-09 | 3.062E-08 | UGT1A1; MAOA; GAA; ALOX15; AKR1B1; ALOX12; PTGS2; CYP2C19; PGD; CYP3A4; CYP19A1; HSD17B10; PTGS1; HSD11B1; CYP2C9; FUT7; PKM; ALOX5; HKDC1; CYP1A2; ALDH1A1; CYP1A1; ALPL; XDH |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.028E-09 | 3.062E-08 | MAP2K1; PTGS2; MMP9; NFKB1; CDC25B; PIK3CA; PIM1; BCL2; CYP1B1; MAPK1; TP53; MET; MCL1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.375E-10 | 6.533E-09 | HSD11B1; CYP2C9; UGT1A1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.629E-09 | 6.896E-08 | MAP2K1; MMP1; MMP2; PIK3CB; PTGS2; HIF1A; MMP9; NFKB1; RXRA; PIK3CA; BCL2; MAPK1; MET; TP53 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.334E-10 | 8.869E-09 | HSD11B1; HSD11B2; UGT1A1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.356E-09 | 4.973E-08 | MAP2K1; PIK3CA; MMP2; MAPK1; PIK3CB; MAPK14; TP53; HIF1A; ESR1; MMP9; MET |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.383E-09 | 3.285E-08 | MAP2K1; PIK3CA; MAPK1; PIK3CB; MAPK14; ESR1; NFKB1; ESR2 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.654E-08 | 2.613E-07 | MAP2K1; PIK3CA; LMNA; BCL2; MAPK1; PIK3CB; TP53; NFKB1; MCL1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 2.095E-08 | 2.843E-07 | PIK3CA; MMP2; PIM1; BCL2; MAPK1; PIK3CB; MAPK14; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.384E-08 | 2.390E-07 | CYP2C9; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.788E-08 | 2.613E-07 | MAP2K1; PIK3CA; MMP2; MAPK1; PIK3CB; ESR1; MMP9; ESR2 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.446E-08 | 3.099E-07 | MAP2K1; PIK3CA; HKDC1; BCL2; MAPK1; PIK3CB; HIF1A; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 4.107E-08 | 4.590E-07 | MAP2K1; PIK3CA; MAPK1; PIK3CB; MAPK14; PTGS2; MMP9; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 7.116E-08 | 7.116E-07 | MAP2K1; RXRA; PIK3CA; MAPK1; PIK3CB; TP53; ESR1; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 8.113E-08 | 7.340E-07 | MAP2K1; PIK3CA; BCL2; MAPK1; PIK3CB; MAPK14; TP53; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.400E-08 | 4.644E-07 | HSD11B1; CYP2C9; UGT1A1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 8.113E-08 | 7.340E-07 | MAP2K1; PIK3CA; BCL2; MAPK1; PIK3CB; MAPK14; TP53; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.753E-07 | 1.448E-06 | MAP2K1; PIK3CA; BCL2; MAPK1; PIK3CB; TP53; NFKB1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.172E-08 | 3.767E-07 | MAP2K1; MMP1; MMP2; MAPK1; MMP9; TP53 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.382E-07 | 1.194E-06 | RXRA; PIK3CA; BCL2; PIK3CB; PTGS2; TP53; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.856E-07 | 2.442E-06 | SYK; CSNK2A1; PIK3CA; BCL2; CDK1; PIK3CB; MAPK14; TP53; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.691E-07 | 2.418E-06 | MAP2K1; PIK3CA; BCL2; MAPK1; PIK3CB; TP53; MMP9; NFKB1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 3.404E-07 | 2.395E-06 | MAP2K1; PIK3CA; CDK1; MAPK1; PIK3CB; MAPK14; CDC25B |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.730E-07 | 2.723E-06 | MAP2K1; RXRA; SYK; PIK3CA; BCL2; MAPK1; PIK3CB; TP53; MET; NFKB1; MCL1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 4.365E-07 | 2.592E-06 | POLB; PKM; SYK; PIK3CA; CDK1; MAPK1; PIK3CB; TP53; NFKB1 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.167E-07 | 1.647E-06 | MAP2K1; RXRA; PIK3CA; MAPK1; PIK3CB; TP53 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.413E-07 | 1.764E-06 | MAP2K1; PIK3CA; PIM1; MAPK1; PIK3CB; NFKB1 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 3.639E-07 | 2.418E-06 | MAP2K1; PIK3CA; MAPK1; PIK3CB; MAPK14; PTGS2 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 4.014E-07 | 2.460E-06 | MAP2K1; PIK3CA; BCL2; MAPK1; PIK3CB; TP53 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 6.990E-07 | 3.590E-06 | MAP2K1; PIK3CA; SYK; MAPK1; PIK3CB; MAPK14 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 5.846E-07 | 3.085E-06 | MAP2K1; PIK3CA; MAPK1; PIK3CB; TP53; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.204E-06 | 5.448E-06 | PIK3CA; ALOX5; BCL2; MAPK1; PIK3CB; MAPK14; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.555E-06 | 1.129E-05 | MAP2K1; PIK3CA; SYK; MAPK1; PIK3CB; MAPK14; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 5.846E-07 | 3.085E-06 | MAP2K1; PIK3CA; MAPK1; PIK3CB; MET; HIF1A |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.687E-06 | 1.141E-05 | RXRA; PIK3CA; MAPK1; PIK3CB; MAPK14; TP53; NFKB1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 9.046E-07 | 4.407E-06 | MAP2K1; PIK3CA; MAPK1; PIK3CB; TP53; MET |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 5.334E-07 | 2.981E-06 | CYP2C9; UGT1A1; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.067E-06 | 4.946E-06 | MAP2K1; PIK3CA; MAPK1; PIK3CB; TP53; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.067E-06 | 4.946E-06 | MAP2K1; PIK3CA; SYK; MAPK1; PIK3CB; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.628E-07 | 3.814E-06 | CYP2C9; UGT1A1; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 8.487E-06 | 3.291E-05 | MAP2K1; PIK3CA; MAPK1; PIK3CB; MAPK14; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 9.472E-06 | 3.529E-05 | MAP2K1; PIK3CA; MAPK1; PIK3CB; MAPK14; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.958E-05 | 6.889E-05 | RXRA; HPGD; TP53; MMP9; MET; ELANE; NFKB1 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.116E-05 | 7.310E-05 | PIK3CA; SYK; MAPK1; PIK3CB; MAPK14; PTGS1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.725E-05 | 1.220E-04 | HCAR2; MAP2K1; PIK3CA; MAPK1; PIK3CB; NFKB1; TSHR |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 5.401E-05 | 1.710E-04 | MAP2K1; PIK3CA; CNR1; MAPK1; PIK3CB; MAPK14; MET |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 4.416E-05 | 1.422E-04 | PTPN1; MAP2K1; PIK3CA; HKDC1; MAPK1; PIK3CB |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.008E-07 | 1.590E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.576E-04 | 4.608E-04 | MAP2K1; PIK3CA; MAPK1; PIK3CB; MAPK14; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.758E-04 | 4.912E-04 | MAP2K1; MAPK1; MAPT; MAPK14; TP53; NFKB1; CDC25B |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.611E-04 | 4.638E-04 | MAP2K1; PIK3CA; BCL2; MAPK1; PIK3CB |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.032E-04 | 3.113E-04 | MAP2K1; PIK3CA; MAPK1; PIK3CB; HIF1A |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.226E-05 | 4.480E-05 | MAP2K1; PIK3CA; MAPK1; PIK3CB; TP53 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 6.972E-05 | 2.136E-04 | MAP2K1; PIK3CA; SYK; MAPK1; PIK3CB |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 5.858E-06 | 2.319E-05 | PIK3CA; PIK3CB; PTGS2; TSHR; PTGS1 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 3.417E-04 | 9.016E-04 | MAP2K1; PIK3CA; BCL2; MAPK1; PIK3CB; MET |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.186E-04 | 3.520E-04 | PIK3CA; MAPK1; PIK3CB; MAPK14; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 2.258E-04 | 6.043E-04 | MAP2K1; PIK3CA; GRK6; MAPK1; PIK3CB; NFKB1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 4.044E-06 | 1.635E-05 | MAP2K1; PIK3CA; MAPK1; PIK3CB; TP53 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 6.972E-05 | 2.136E-04 | SYK; CSNK2A1; BCL2; PTGS2; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.891E-05 | 6.779E-05 | SLCO1B1; RXRA; CA2; SLCO1B3; CYP3A4 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 2.145E-04 | 5.821E-04 | PIK3CA; MMP2; PIK3CB; MAPK14; MMP9 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 3.732E-04 | 9.430E-04 | MAP2K1; PIK3CA; MAPK1; PIK3CB; MAPK14 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 6.331E-04 | 1.467E-03 | MAP2K1; PIK3CA; MAPK1; PIK3CB; MET; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 4.135E-04 | 1.007E-03 | PIK3CA; CSNK2A1; PIK3CB; TP53; NFKB1 |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 3.997E-04 | 9.863E-04 | MAP2K1; PIK3CA; SYK; MAPK1; PIK3CB |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 5.369E-04 | 1.275E-03 | MAP2K1; PIK3CA; SYK; MAPK1; PIK3CB |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 5.037E-04 | 1.212E-03 | MAP2K1; PIK3CA; MAPK1; PIK3CB; MAPK14 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 6.081E-04 | 1.426E-03 | PIK3CA; BCL2; MAPK1; PIK3CB; MAPK14 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 3.320E-06 | 1.372E-05 | ALOX5; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 8.170E-04 | 1.824E-03 | MAP2K1; PIK3CA; MAPK1; PIK3CB; PTGS2 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 8.170E-04 | 1.824E-03 | PIK3CA; PIM1; BCL2; PIK3CB; MCL1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 2.703E-06 | 1.141E-05 | PKM; PIK3CA; HKDC1; MAPK1; PIK3CB |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.075E-03 | 2.322E-03 | BACE1; APP; MAPK1; MAPT; HSD17B10 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.390E-03 | 2.840E-03 | SYK; BCL2; MAPK1; MAPK14; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 6.798E-03 | 1.234E-02 | POLB; PIK3CA; PIK3CB; TP53; NFKB1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 5.218E-03 | 9.719E-03 | RXRA; PIK3CA; PIK3CB; NFKB1 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 1.714E-02 | 2.807E-02 | MAP2K1; PIK3CA; MAPK1; PIK3CB |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.089E-03 | 2.325E-03 | PIK3CA; ALOX12; PIK3CB; MAPK14 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.053E-02 | 1.802E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.614E-03 | 3.262E-03 | PTPN1; PIK3CA; PIK3CB; NFKB1 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 6.973E-04 | 1.596E-03 | MAP2K1; PIK3CA; MAPK1; PIK3CB |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 7.414E-03 | 1.316E-02 | MAP2K1; PIK3CA; MAPK1; PIK3CB |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 8.256E-04 | 1.824E-03 | MAP2K1; MMP2; MAPK1; MAPK14 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 9.322E-04 | 2.036E-03 | PIK3CA; PIK3CB; TP53; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 3.581E-04 | 9.194E-04 | MAPK1; MAPK14; PTGS2; NFKB1 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 1.218E-03 | 2.543E-03 | CNR1; MAPK1; MAPK14; PTGS2 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.679E-04 | 4.761E-04 | PIK3CA; MAPK1; PIK3CB; HIF1A |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 1.917E-02 | 3.114E-02 | MAP2K1; CDK1; MAPK1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.958E-02 | 3.153E-02 | CDK1; TP53; CDC25B |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 3.772E-04 | 9.430E-04 | PTPN1; CSNK2A1; MAPK1; MET |
| hsa01200 | Carbon metabolism_Homo sapiens_hsa01200 | 1.533E-02 | 2.532E-02 | PKM; HKDC1; PGD |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.105E-02 | 1.874E-02 | PIK3CA; PIK3CB; NFKB1 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 7.797E-03 | 1.372E-02 | MAP2K1; CDK1; MAPK1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 7.320E-03 | 1.312E-02 | MAPK1; MAPK14; NFKB1 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 5.587E-03 | 1.031E-02 | PIK3CA; PIK3CB; MET |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 5.008E-03 | 9.421E-03 | MAPK1; MAPK14; NFKB1 |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 3.118E-02 | 4.895E-02 | MAP2K1; MAPK1 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 3.804E-03 | 7.300E-03 | MAPK14; MET; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 3.348E-03 | 6.491E-03 | MAPK1; MAPK14; NFKB1 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 3.049E-05 | 1.034E-04 | HSD11B2; PIK3CA; MAPK1; PIK3CB |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.303E-03 | 4.511E-03 | MAPK1; MAPK14; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.375E-05 | 1.125E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 2.189E-03 | 4.332E-03 | UGT1A1; GAA; HKDC1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 9.118E-06 | 3.465E-05 | MAP2K1; RXRA; MAPK1; TP53 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.140E-02 | 3.416E-02 | MAOA; NFKB1 |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 1.672E-03 | 3.344E-03 | BCL2; MAPK14; TP53 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 1.162E-03 | 2.453E-03 | PIK3CA; HKDC1; PIK3CB |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.239E-03 | 2.559E-03 | UGT1A1; CYP3A4; XDH |
| hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 1.128E-02 | 1.897E-02 | MAP2K1; MAPK1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.495E-04 | 9.097E-04 | GAA; HKDC1; AKR1B1 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 6.817E-03 | 1.234E-02 | MAP2K1; MAPK1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.007E-02 | 1.740E-02 | POLB; APEX1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 9.491E-03 | 1.654E-02 | HKDC1; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.191E-02 | 1.985E-02 | UGT1A1; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 4.973E-03 | 9.421E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.074E-04 | 5.712E-04 | CYP1A2; XDH |
| hsa00524 | Butirosin and neomycin biosynthesis_Homo sapiens_hsa00524 | 2.279E-02 | 3.609E-02 | HKDC1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | SLC6A2 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; HIF1A; BCL2 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | CNR1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| NA: NA | Myocardial ischaemia-reperfusion injury | NA | ELANE |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | ELANE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | BCL2; ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; ELANE; ELANE; MAPK14 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; CNR1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | CNR1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PKM; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; CNR1; CDK1; SLC6A2; ESR1; CNR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; CNR1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | CNR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; SLC6A2; SLC6A2; SLC6A2; SLC6A2 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chemotherapy-induced nausea | R11 | CNR1 |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; HSD11B1; AKR1B1; PTPN1; CNR1; CNR1; CNR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | ELANE; ELANE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | SLC6A2; SLC6A2 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| J00-J99: Diseases of the respiratory system | Bronchiectasis | J47, Q33.4 | ELANE |
| C00-D49: Neoplasms | Cancer | C00-C96 | MET; MCL1; CSNK2A1; SYK; PIK3CA; CA1; CA9; MMP2; NQO2; PTGS2; HIF1A; CDK1; MAPK1; MAPK14; MMP9; NFKB1; PIM1; CDC25B; BCL2; BCL2; TP53; PIK3CB; ESR1; ESR1; APP |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; ALOX5; HCAR2 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HCAR2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; PTGS2; PTGS2; MAPK14; MMP1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; SYK; SYK; ELANE; PTGS2 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HCAR2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; PTGS2; XDH |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; CNR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | CNR1 |
| J00-J99: Diseases of the respiratory system | Pulmonary disease | J00-J99 | ELANE |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anorexia | F50.0-F50.1 | CNR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | BCL2; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; MAPK14; BCL2 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; CNR1; CNR1 |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; PTGS2; APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; HSD11B2; PTPN1; PTPN1; PTGS2; CNR1; NFKB1; HCAR2 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; PKM; SYK; PIK3CA; CA9; MMP2; HIF1A; MAPK1; MMP9; TP53; PIK3CB |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| C00-D49: Neoplasms | Cutaneous T-cell lymphoma | C84.0, C84.1 | RXRA |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; BCL2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; SLC6A2; CYP3A4 |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | ELANE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CNR1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| J00-J99: Diseases of the respiratory system | Mucolytic | J00-J99 | ELANE |
| C00-D49: Neoplasms | Multiple myeloma | C90 | BCL2 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; SLC6A2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; CNR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; ALOX5; SYK; ELANE; PTGS2; PTGS2; PTGS2; PTGS2; MAPK14; MMP1; CNR2 |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2; MAPK14 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | ELANE; ELANE; ELANE; MAPK14 |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; SYK |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | CNR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK; PIK3CB |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1; MMP9; TP53 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; PTGS2 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9; NQO2; CDK1; BCL2; ESR1; ESR1 |
| NA: NA | Acute respiratory distress syndrome | NA | ELANE; ELANE; ELANE; MAPK14 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; SLC6A2; HCAR2 |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; MAPK14 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; CNR2 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1; PTGS2; PTGS2; CNR1; CNR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | CNR1 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | CNR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; PTGS1; ESR1 |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
| J00-J99: Diseases of the respiratory system | Pulmonary emphysema | J43 | ELANE |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; PTPN1; CNR1; CNR1; CNR1; CNR1; CNR1; CNR1; SLC6A2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; SYK; ELANE; PTGS1; PTGS2; MAPK14; CNR2 |
| NA: NA | Inflammatory diseases | NA | MAPK14 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; MAPK14; CNR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CNR1; CA2 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CNR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; HCAR2 |